Tyche Industries Ltd banner
T

Tyche Industries Ltd
BSE:532384

Watchlist Manager
Tyche Industries Ltd
BSE:532384
Watchlist
Price: 122.92 INR -0.45% Market Closed
Market Cap: ₹1.3B

EV/GP

3.2
Current
21%
More Expensive
vs 3-y average of 2.7

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
3.2
=
Enterprise Value
₹837.3m
/
Gross Profit
₹306.5m

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
3.2
=
Enterprise Value
₹837.3m
/
Gross Profit
₹306.5m

Valuation Scenarios

Tyche Industries Ltd is trading above its 3-year average

If EV/GP returns to its 3-Year Average (2.7), the stock would be worth ₹101.23 (18% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-18%
Maximum Upside
+103%
Average Upside
43%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 3.2 ₹122.92
0%
3-Year Average 2.7 ₹101.23
-18%
5-Year Average 2.7 ₹101.23
-18%
Industry Average 6.5 ₹249.86
+103%
Country Average 6.5 ₹249.86
+103%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
Market Cap EV/GP P/E
IN
Tyche Industries Ltd
BSE:532384
1.3B INR 3.2 18.7
US
Eli Lilly and Co
NYSE:LLY
910.2B USD 17.4 44.1
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 8.7 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 6.3 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 6.2 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 7.4 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 5.8 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 160.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 5.3 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 4.2 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
117.2B USD 4.3 16.6
P/E Multiple
Earnings Growth PEG
IN
T
Tyche Industries Ltd
BSE:532384
Average P/E: 22
18.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
44.1
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.6
16%
1

Market Distribution

Lower than 78% of companies in India
Percentile
22st
Based on 2 475 companies
22st percentile
3.2
Low
0.2 — 4.1
Typical Range
4.1 — 10.8
High
10.8 —
Distribution Statistics
India
Min 0.2
30th Percentile 4.1
Median 6.5
70th Percentile 10.8
Max 34 392.2

Tyche Industries Ltd
Glance View

Market Cap
1.3B INR
Industry
Pharmaceuticals

Tyche Industries Ltd. engages in the manufacture and processing of active pharmaceutical ingredients and intermediates. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2000-09-25. The firm primarily manufactures bulk drug intermediates. Its APIs include Sertraline HCI, Racecadotril, Palonosetron HCI, Silodosin, Solifenacin Succinate, Tamsulosin HCI, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide Fumarate, Atazanavir, Rupatadine Fumarate, Glucosamine HCI, Glucosamine Sulfate KCL, Glucosamine Sulfate NaCl, Nitrofurantoin Monohydrate, Nitrofurantoin Anhydrous and Nitrofurantoin Macrocrystal. Its intermediaries include 6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophene, 3-Fluoro-4-methoxy acetophenone, 3-Hydroxymethyl quinuclidine HCl, (RS)-3-Quinuclidinol, 3-Quinuclidinone Hydrochloride and 1-Benzylpiperidine-4-Carboxaldehyde (BPCA). Its nutraceuticals include Glucosamine Hydrochloride, Glucosamine Sulfate Potassium Chloride and Glucosamine Sulfate Sodium Chloride.

TYCHE Intrinsic Value
96.14 INR
Overvaluation 22%
Intrinsic Value
Price ₹122.92
T
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett